Please wait while the formulary information is being retrieved.
ELAHERE (mirvetuximab soravtansine-gynx)
- folate receptor alpha positive epithelial ovarian cancer
5 mg/mL intravenous solution
- Infuse 6 mg/kg by intravenous route every 3 weeks
Default screening record
- Infuse 6 mg/kg by intravenous route every 3 weeks
- Infuse 5 mg/kg by intravenous route every 3 weeks
- Infuse 4 mg/kg by intravenous route every 3 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactation
Contraindicated
- Peripheral neuropathy
- Pregnancy
Severe
Moderate
- None
ELAHERE (mirvetuximab soravtansine-gynx)
- folate receptor alpha positive epithelial ovarian cancer
- Anemia
- Disorder of cornea
- Hypoalbuminemia
- Hypomagnesemia
- Increased alanine transaminase
- Increased alkaline phosphatase
- Increased aspartate transaminase
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Acute abdominal pain
- Constipation
- Diarrhea
- Dry eye
- Fatigue
- Nausea
- Peripheral sensory neuropathy
More Frequent
Severe
Less Severe
- Hypokalemia
- Thrombocytopenic disorder
- Uveitis
- Vision loss
- Abdominal distension
- Anorexia
- Arthralgia
- Cataracts
- Dyspnea
- Hypoesthesia
- Interstitial lung disease
- Interstitial pneumonitis
- Myalgia
- Ocular pain
- Paresthesia
- Peripheral motor neuropathy
- Photophobia
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Mirvetuximab soravtansine-gynx
Safety and effectiveness not established in pediatrics.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatrics.
Mirvetuximab Soravtansine-gynx
- Severity Level:
D
- Additional Notes: Based on drug pharmacology, developmental toxicity is possible
Contraindicated
Mirvetuximab Soravtansine-gynx
Mfr rec avoid breastfeeding during tx and for 1 month after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr rec avoid breastfeeding during tx and for 1 month after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause eye problems that can be serious (such as changes in vision, decreased/blurred vision, dry eyes, eye redness/pain, sensitivity to light). Your doctor will have you do eye exams before starting and during treatment with this medication. Your doctor may also prescribe eye medications or products (such as lubricant eye drops, steroids such as prednisolone) to lessen the risk or severity of eye problems. Tell your doctor right away if you have new or worsening eye symptoms.
| Folate receptor alpha positive epithelial ovarian cancer | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| 0-9 | A-Z |
|---|---|
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
Formulary Reference Tool